Levalbuterol Solution
Product Images NDC 65862-945

This is a description of a figure showing the mean percent change from baseline FEV (forced expiratory volume) for different medications administered to adults and adolescents over 12 years old on Day 1. The medications include Lev1.25, Lev0.63, Rac25, and Placebo (PBO), and the number of patients in each group is also provided. The Y-axis shows the mean change in FEV as a percentage, and the X-axis shows time in hours. There is no other information available.*

Levalbuterol Inhalation Solution is a USP approved medicine. It comes in the form of a 0.31 mg/3 mL sterile unit-dose vial. The unidose vial is stored in a protective foil pouch that needs to be opened at the center seal area. The packet contains twelve 3mL vials. Each vial of this inhalation solution contains 0.31 mg of levalbuterol. It should be used within two weeks after the foil pouch is opened. The pharmacist should include patient instructions while providing the medication. Patients are not suggested to exceed the recommended dosage. The unopened vial should be stored at a temperature between 20°C and 25°C. The medication is supplied by Aurobindo Pharma USA, Inc. from New Jersey.*

Levalbuterol Inhalation Solution, USP is a medication available in sterile 3mL unit-dose vials for oral inhalation only. It contains 0.31mg of levalbuterol, a potent drug used to treat bronchospasms caused by conditions such as asthma and chronic obstructive pulmonary disease (COPD). Each box contains 24 unit-dose vials. This product is manufactured and sold by Aurobindo. The medication should be stored at room temperature, away from light and moisture. Discard vials after use and do not share with others. This medication is available only on prescription and should be used only as directed by a medical professional.*

Levalbuterol Inhalation Solution is a medication available in single-dose vials. Each vial contains 0.63 mg of levalbuterol in an aqueous solution with added salts to adjust pH. The medication is for oral inhalation only and should be used as directed by a physician. Once a vial has been removed from its protective pouch, it should be used within one week and discarded if unused. The medication must be stored at controlled room temperature to maintain potency and protect it from light. This product is distributed by Aurobindo Pharma USA, Inc.*

Levalbuterol Inhalation Solution is an oral inhalation medication that comes in a package of 24-unit dose vials, with each dose containing .63mg of levalbuterol and .73mg of racemic albuterol. The medication should be used only as directed by a physician, and must be protected from light and stored at controlled room temperature. Each unidose vial should be used within one week after opening the protective pouch. The solution is an aqueous solution containing edetate sodium, sodium chloride, and sulfuric acid to adjust the pH. The medication does not contain preservatives.*

This is a description for a medication named Levalbuterol Inhalation Solution, used for oral inhalation. It comes in 12 single-use vials, each containing 125 mg of levalbuterol and 144 mg of yrochirde USP in an aqueous solution. The solution also contains other ingredients such as sodium chode and suluc acid, which are used to adjust the pH. The package includes instructions for use and storage guidelines to maintain the product's efficacy, such as protecting it from light and keeping it at controlled room temperature. The medication is distributed by Aurobindo Pharma USA and made in India.*

The text is a product label for a medication called Levalbuterol Inhalation Solution, which is intended for oral inhalation only. It is packaged in 24 x 3 mL sterile unit-dose vials, each containing 1.25 mg/3 mL levalbuterol. The medication is distributed by Aurobindo Pharma USA, Inc. and made in India. The text advises that the medication should be used only as directed by a physician and cautions that it should be kept out of reach of children, protected from light, and stored at a temperature between 20° and 25°C. Once the unit-dose vial pouch is opened, the vial should be used within two weeks. If removed from the pouch, the individual vial should be used within one week. The product label includes information about the active and inactive ingredients and includes instructions for use, which should be reviewed before use.*

This appears to be a graph displaying the mean percent change from baseline forced expiratory volume on day 29 in adults and adolescents over 12 years old. It shows four treatments with corresponding sample sizes: Lev1.25 (n=57), Lev 063 (n=63), Rac 25 (n=65), and PBO (n=63). The y-axis measures the mean change in FEV in percentages, with 15% as the highest value shown. The x-axis represents time in hours.*

The text provides a figure with the mean percent change from baseline FEV in children between 6 to 11 years of age. The figure includes different treatment groups with the number of participants and the corresponding treatment regimen. The x-axis displays time in hours, and the y-axis shows the mean percent change from baseline FEV. No further information is available.*

The text is not-available since it only mentions the name of two figures without providing any additional information.*